A5039835286- Atrial Fibrillation Management and Outcomes
- Lipoproteins and Cardiovascular Health
- Venous Thromboembolism Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Arrhythmias and Treatments
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Diabetes Treatment and Management
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac Imaging and Diagnostics
- Blood Pressure and Hypertension Studies
- Cardiac pacing and defibrillation studies
- Acute Myocardial Infarction Research
- Cardiac electrophysiology and arrhythmias
- Liver Disease Diagnosis and Treatment
- Pharmaceutical Economics and Policy
- Cardiovascular Effects of Exercise
- Cardiac Health and Mental Health
- Inflammatory mediators and NSAID effects
- Eicosanoids and Hypertension Pharmacology
- COVID-19 Clinical Research Studies
- Adipokines, Inflammation, and Metabolic Diseases
- Cardiovascular Function and Risk Factors
- Cardiac tumors and thrombi
- Diet, Metabolism, and Disease
- Fatty Acid Research and Health
Johns Hopkins University
2013-2025
University Hospitals of Leicester NHS Trust
2024
University of Colorado Anschutz Medical Campus
2022-2024
Duke University
2023-2024
Veterans Health Administration
2023-2024
Cigna (United States)
2024
Vertex Pharmaceuticals (United States)
2023
Cooper Clinic
2020
Presbyterian St. Luke's Medical Center
2020
Hope Heart Institute
2020
Abstract Protectins are newly identified natural chemical mediators that counter leukocyte activation to promote resolution of inflammation. In this study, we provide the first evidence for protectin D1 (PD1, 10R,17S-dihydroxy-docosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoic acid) formation from docosahexaenoic acid in human asthma vivo and PD1 counterregulatory actions allergic airway 17S-hydroxy-docosahexaenoic were present exhaled breath condensates healthy subjects. Of interest, levels...
Cumulative exposure to low-density lipoprotein cholesterol (LDL-C) is a key driver of atherosclerotic cardiovascular disease (ASCVD) risk. An armamentarium therapies achieve robust and sustained reduction in LDL-C can reduce ASCVD The gold standard for assessment ultracentrifugation but routine clinical practice usually calculated the most accurate calculation obtained through Martin/Hopkins equation. For primary prevention, consideration estimated risk frames decision making regarding use...
Acute lung injury (ALI) is a severe illness with excess mortality and no specific therapy. In its early exudative phase, neutrophil activation accumulation in the lead to hypoxemia, widespread tissue damage, respiratory failure. clinical trials, inhibition of proinflammatory mediators has not proven effective. this study, we pursued new investigative strategy that emphasizes promoting resolution from injury. A spontaneously resolving experimental murine model ALI acid aspiration was...
Background— Lipoprotein(a) [Lp(a)] is an emerging risk factor for cardiovascular disease. Currently, there are few available therapies to lower Lp(a). We sought evaluate the impact of AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9 (PCSK9), on Methods and Results— As part LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined Statin Therapy (LAPLACE)–Thrombolysis in Myocardial Infarction (TIMI) 57 trial, 631 patients with hypercholesterolemia...
Abstract OBJECTIVE We investigated the prognostic performance of ST2 with respect to cardiovascular death (CVD) and heart failure (HF) in patients non–ST-elevation acute coronary syndrome (NSTE-ACS) a large multinational trial. BACKGROUND Myocytes that are subjected mechanical stress secrete ST2, soluble interleukin-1 receptor family member is associated HF after STE-ACS. METHODS measured high-sensitivity assay all available baseline samples (N = 4426) enrolled Metabolic Efficiency With...
We sought to evaluate the effect of potent platelet inhibition after acute coronary syndrome on total (ie, first and recurrent) occurrences any primary outcome events (e.g., cardiovascular death, myocardial infarction, stroke) as well other ischemic events, such urgent revascularization, (severe) recurrent ischemia, transient attacks, arterial thrombotic events.In PLATelet patient Outcomes (PLATO) study, 18 624 patients presenting with syndromes randomly received ticagrelor (n=9333) or...
Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors reduce low-density lipoprotein cholesterol (LDL-C) and improve outcomes in the general population. HIV-infected individuals are at increased risk for cardiovascular events have high rates of dyslipidemia hepatitis C virus (HCV) coinfection, making PCSK9 inhibition a potentially attractive therapy.We studied 567 participants from clinic-based cohort to compare levels patients with HIV/HCV coinfection (n=110) those HIV infection alone...
he way we practice medicine during the coronavirus disease 2019 (CO-VID-19) pandemic is unprecedented.The healing power of face-to-face visit and human touch are no longer privileges afforded to us.Clinical decisions previously made on basis appropriate diagnostic testing careful contemplation now intuition because a lack resources.Therapies administered data from rigorously conducted clinical trials have been replaced with therapies that based anecdotal evidence.The novel has, in few...
Abstract Lowering low‐density lipoprotein cholesterol (LDL‐C) is a cornerstone for the prevention of atherosclerotic heart disease, improving clinical outcomes and reducing vascular mortality in patients with hypercholesterolemia. The benefits LDL‐C reduction appear to extend even starting as low 60–80 mg/dL prior initiating therapy. Statins are first‐line agents treating hypercholesterolemia effective LDL‐C, but many unable achieve their optimal lipid targets despite intensive statin...